Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$11.4M
4 rounds on record
Latest round
$11M
Venture round · Jan 2024 · 2 yr ago
Team
11-50
employees, estimated range
Backers
1
Walnut Venture Associates
The money's age
Long since its last round
31 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jan 2024 $11M — SEC Form D
Convertible Note Jun 2020 $398k — SEC Form D
Debt Financing Nov 2019 $511k — SEC Form D
Debt Financing Oct 2018 $538k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Octagon Therapeutics, Inc. sec
Founders and leadersfrom filings, registers and the company's site
Fred AusubelExecutive Officer, DirectorSEC Form D
Isaac StonerExecutive Officer, DirectorSEC Form D
Shen YuExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
TrexBioVenture round $42.3M · 22 mo ago • Founded 2021 • 51-200 employees
Decoding Human T issue Biology to C reate Revolutionary T herapeutics. TRexBio is developing immunoregulatory medicines designed to restore…
Coultreon Biopharma51-200 employees
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Odyssey is on a mission to transform the standard of care for patients affected by autoimmune and inflammatory conditions.
Viridian TherapeuticsVenture round $27M · 6 yr ago • Founded 2020 • 51-200 employees
Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions.

Overview

A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the glycoproteome.

People

Fred Ausubel
Executive Officer, Director
Isaac Stoner
Executive Officer, Director
Shen Yu
Executive Officer, Director
Paul Goldenheim
Director
Thorne Sparkman
Director
Ronald Lennox
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Allston United States
HQ
10-50 est. staff

Financials

Total raised
$12.4M
Latest round
Venture - Series Unknown
Funding rounds
4
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $11M Details
Convertible Note 2020 $398k Details
Debt Financing 2019 $511k Details
Debt Financing 2018 $538k Details